• Technology

    Technology

    Vector, target, indication getting the new combination to the clinics
  • About us

    About us

    Developing a single dose treatment for rheumatoid arthritis
  • Clinical program

    Clinical program

    10 years of development ready for clinical trial
  • Technology

    Technology

    Single dose treatment for chronic diseases
  • Technology

    Technology

    Vector, target, indication getting the new combination to the clinics
  • About us

    About us

    Developing a single dose treatment for rheumatoid arthritis
  • Clinical program

    Clinical program

    10 years of development getting ready for clinical trial
  • Technology

    Technology

    Single dose treatment for chronic diseases
  • HOME 767 310 02
  • HOME 767 310 01

About us

Arthrogen is an Amsterdam based biopharmaceutical clinical-stage company developing local gene therapy for inflammatory diseases, using viral mediated gene transfer.

Technology

The therapeutic vectors are derived from natural occurring adeno-associated viruses (AAV) that are not pathogenic in humans.

Clinical trials

The first target indication is in the field of rheumatic diseases. Arthrogen has started a phase 1b clinical trial in The Netherlands and in Canada.

Development

It is Arthrogen’s vision that new gene therapies will contribute to the improvement of health of patients and to the reduction of healthcare cost.

For professionals to learn more on our clinical development program, please follow this link….

For patients to learn more on our clinical development program, please follow this link….

Latest news

Robert Jan Lamers (CEO) and Janneke Meulenberg (COO) will be present at the J.P. Morgan Healthcare conference, held in San Francisco in January 2018. Interesed in a 'meet&greet'? Send your request to This email address is being protected from spambots. You need JavaScript enabled to view it. for opportunities.

Arthrogen will be represented by Janneke Meulenberg (COO) and Ingrid de Vries (Research Technician) at the Cell Therapy Manufacturing & Gene Therapy Congress 6 – 7 December 2017 RAI, Amsterdam.

Robert Jan Lamers (CEO) will be present at Phacilitate Cell & Gene Therapy Europe 2017 in Berlin where Janneke Meulenberg, COO, will join the speaker panel.

Arthrogen's COO, Janneke Meulenberg, will present Wednesday September 13 a case study on: Production Platforms for RA Gene Therapy Applications at the'Cell and Gene Therapy Manufacturing' conference in London

Appeal by the Dutch Arthritis Association: http://www.reumafonds.nl/informatie-voor-doelgroepen/patienten/help-mee/neem-deel-aan-onderzoek

Arthrogen to be present at the EULAR Annual European Congress of Rheumatology, Madrid June 14-17, 2017

Arthrogen’s CEO Robert Jan Lamers to present at the May 22-23, 2017 BioEquity, Paris

Arthrogen to be present at the American Society of Gene & Cell Therapy, ASGCT annual meeting, Washington, DC May 10-13, 2017

Arthrogen’s CEO Robert Jan Lamers to present at the May 3, 2017 Investment Summit for Advanced Therapies, London

Arthrogen in the news: http://labiotech.eu/arthrogen-gene-therapy-rheumatoid-arthritis/

Arthrogen announces approval for Phase Ib study with gene therapy ART-I02 in patients with rheumatoid arthritis.

New publication: Empty Capsids and Macrophage Inhibition/Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic Mice....

Latest publications

Empty Capsids and Macrophage Inhibition/Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic Mice....

Intra-articular etanercept treatment in inflammatory arthritis...

Preclinical Potency and Biodistribution Studies of an AAV 5 Vector...

Safety, Biodistribution, and Efficacy of an AAV-5 Vector Encoding Human Interferon-Beta (ART-I02)...